Naringenin, a citrus flavonoid, inhibits apoB secretion from HepG2 cells, an effect associated with selective inhibition of ACAT-2 expression

2000 ◽  
Vol 151 (1) ◽  
pp. 289
Author(s):  
NicaM. Borradaile ◽  
LisaJ. Wilcox ◽  
LindaE. de Dreu ◽  
MurrayW. Huff
2008 ◽  
Vol 49 (10) ◽  
pp. 2218-2229 ◽  
Author(s):  
Emma M. Allister ◽  
Erin E. Mulvihill ◽  
P. Hugh R. Barrett ◽  
Jane Y. Edwards ◽  
Lindsey P. Carter ◽  
...  

2002 ◽  
Vol 366 (2) ◽  
pp. 531-539 ◽  
Author(s):  
Nica M. BORRADAILE ◽  
Linda E. de DREU ◽  
Lisa J. WILCOX ◽  
Jane Y. EDWARDS ◽  
Murray W HUFF

Diets containing the soya-derived phytoestrogens, genistein and daidzein, decrease plasma cholesterol in humans and experimental animals. The mechanisms responsible for the hypocholesterolaemic effects of these isoflavones are unknown. The present study was conducted to determine if genistein and daidzein regulate hepatocyte cholesterol metabolism and apolipoprotein (apo) B secretion in cultured human hepatoma (HepG2) cells. ApoB secretion was decreased dose-dependently by up to 63% and 71% by genistein and daidzein (100μM; P<0.0001) respectively. In contrast, no effect on apoAI secretion was observed. Cellular cholesterol synthesis was inhibited 41% by genistein (100μM; P<0.005) and 18% by daidzein (100μM; P<0.05), which was associated with significant increases in 3-hydroxy-3-methylglutaryl-CoA reductase mRNA. Cellular cholesterol esterification was decreased 56% by genistein (100μM; P<0.04) and 29% by daidzein (100μM; P<0.04); however, mRNA levels for acyl-CoA:cholesterol acyltransferase (ACAT) 1 and ACAT2 were unaffected. At 100μM, both isoflavones equally inhibited the activities of both forms of ACAT in cells transfected with either ACAT1 or ACAT2. Genistein (100μM) and daidzein (100μM) significantly decreased the activity of microsomal triacylglycerol transfer protein (MTP) by 30% and 24% respectively, and significantly decreased MTP mRNA levels by 35% and 55%. Both isoflavones increased low-density lipoprotein (LDL)-receptor mRNA levels by 3- to 6-fold (100μM; P<0.03) and significantly increased the binding, uptake and degradation of 125I-labelled LDL, suggesting that enhanced reuptake of newly secreted apoB-containing lipoproteins contributed to the net decrease in apoB secretion. These results indicate that genistein and daidzein inhibit hepatocyte apoB secretion through several mechanisms, including inhibition of cholesterol synthesis and esterification, inhibition of MTP activity and expression and increased expression of the LDL-receptor.


2005 ◽  
Vol 135 (4) ◽  
pp. 702-706 ◽  
Author(s):  
Pratibha V. Nerurkar ◽  
Laurel Pearson ◽  
Jimmy T. Efird ◽  
Khosrow Adeli ◽  
Andre G. Theriault ◽  
...  

2011 ◽  
Vol 59 (9) ◽  
pp. 4496-4503 ◽  
Author(s):  
Yuguang Lin ◽  
Mario A. Vermeer ◽  
Wil Bos ◽  
Leo van Buren ◽  
Eric Schuurbiers ◽  
...  

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Mario A. Vermeer ◽  
Yuguang Lin ◽  
Wil Bos ◽  
Leo Buren ◽  
Eric Schuurbiers ◽  
...  

1996 ◽  
Vol 93 (21) ◽  
pp. 11991-11995 ◽  
Author(s):  
H. Jamil ◽  
D. A. Gordon ◽  
D. C. Eustice ◽  
C. M. Brooks ◽  
J. K. Dickson ◽  
...  

2019 ◽  
Vol 18 (9) ◽  
pp. 1258-1266 ◽  
Author(s):  
Sakunie Sawai ◽  
Mas Sahidayana Mohktar ◽  
Wan Kamarul Zaman Wan Safwani ◽  
Thamil Selvee Ramasamy

Background: Konjac Glucomannan (KGM) is a water-soluble dietary fibre extracted from Amorphophallus konjac K. Koch (Araceae). Konjac fibre has been clinically proven as an effective antioxidant agent in weight control but its traditionally known tumour suppression property remains to be explored. Objective: The main objective of this study is to determine the potential anti-proliferative effect of KGM on cancer and normal human liver cell lines, HepG2 and WRL68, respectively. Method: HepG2 and WRL68 cells were treated with KGM, D-mannose, KGM-D-mannose and 5-fluorouracil. The morphological changes in those treated cells were observed. Cytotoxic effect of the treatments on cell viability and proliferation, and apoptosis genes expression were assessed by cytotoxicity assay, flow cytometry and RT-PCR analyses. Results: The results show that KGM treatment resulted in reduced viability of HepG2 cells significantly, in line with the apoptosis-like morphological changes. Up-regulation of BAX and down-regulation of BCL2 genes as reflected by high Bax to Bcl 2 ratio suggests that the inhibitory effect of KGM on HepG2 cells most likely via Bcl2/Bax protein pathway. Despite the effectiveness of standard drug 5-FU in suppressing the viability and proliferation of HepG2 cells, it however, exhibited no selective inhibition of cancer cells as compared to KGM. Conclusion: Current findings suggested that KGM is a potential anti-cancer compound/drug entity, which could be an alternative preventive agent against liver cancer.


2000 ◽  
Vol 111 (2) ◽  
pp. 432-440 ◽  
Author(s):  
Davide Gibellini ◽  
Alessandra Bassini ◽  
Maria Carla Re ◽  
Cristina Ponti ◽  
Sebastiano Miscia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document